The contribution of muscle, kidney, and splanchnic tissues to leucine transamination in humans

被引:5
作者
Garibotto, Giacomo [1 ,2 ]
Verzola, Daniela [1 ,2 ]
Vettore, Monica [3 ]
Tessari, Paolo [3 ]
机构
[1] Univ Genoa, Dept Internal Med, Nephrol Dialysis & Transplantat Clin, Genoa, Italy
[2] IRCCS AOU San Martino IST, Genoa, Italy
[3] Univ Padua, Metab Div, Dept Med, Padua, Italy
关键词
leucine; transamination; BCAA; ketoacids; skeletal muscle; kidney; AMINO-ACID-METABOLISM; STABLE-ISOTOPE; PHENYLALANINE KINETICS; ALPHA-KETOISOCAPROATE; PROTEIN-TURNOVER; WHOLE-BODY; MODEL; OXIDATION; FOREARM; VALINE;
D O I
10.1139/cjpp-2017-0439
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The first steps of leucine utilization are reversible deamination to alpha-ketoisocaproic acid (alpha-KIC) and irreversible oxidation. Recently, the regulatory role of leucine deamination over oxidation was underlined in rodents. Our aim was to measure leucine deamination and reamination in the whole body, in respect to previously determined rates across individual organs, in humans. By leucine and KIC isotope kinetics, we determined whole-body leucine deamination and reamination, and we compared these rates with those already reported across the sampled organs. As an in vivo counterpart of the "metabolon" concept, we analysed ratios between oxidation and either deamination or reamination. Leucine deamination to KIC was greater than KIC reamination to leucine in the whole body (p = 0.005), muscles (p = 0.005), and the splanchnic area (p = 0.025). These rates were not significantly different in the kidneys. Muscle accounted for approximate to 60% and approximate to 78%, the splanchnic bed for approximate to 15% and approximate to 15%, and the kidney for approximate to 12% and approximate to 18%, of whole-body leucine deamination and reamination rates, respectively. In the kidney, percent leucine oxidation over either deamination or reamination was >3-fold greater than muscle and the splanchnic bed. Skeletal muscle contributes by the largest fraction of leucine deamination, reamination, and oxidation. However, in relative terms, the kidney plays a key role in leucine oxidation.
引用
收藏
页码:382 / 387
页数:6
相关论文
共 38 条
  • [1] METABOLISM OF BRANCHED-CHAIN AMINO-ACIDS IN ALTERED NUTRITION
    ADIBI, SA
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1976, 25 (11): : 1287 - 1302
  • [2] [Anonymous], ADV NUTR, V2, P445, DOI [10.3945/an.111.000737, DOI 10.3945/AN.111.000737]
  • [3] Low-protein diets for chronic kidney disease patients: the Italian experience
    Bellizzi, Vincenzo
    Cupisti, Adamasco
    Locatelli, Francesco
    Bolasco, Piergiorgio
    Brunori, Giuliano
    Cancarini, Giovanni
    Caria, Stefania
    De Nicola, Luca
    Di Iorio, Biagio R.
    Di Micco, Lucia
    Fiaccadori, Enrico
    Garibotto, Giacomo
    Mandreoli, Marcora
    Minutolo, Roberto
    Oldrizzi, Lamberto
    Piccoli, Giorgina B.
    Quintaliani, Giuseppe
    Santoro, Domenico
    Torraca, Serena
    Viola, Battista F.
    [J]. BMC NEPHROLOGY, 2016, 17
  • [4] LEUCINE AND PHENYLALANINE KINETICS DURING MIXED MEAL INGESTION - A MULTIPLE TRACER APPROACH
    BIOLO, G
    TESSARI, P
    INCHIOSTRO, S
    BRUTTOMESSO, D
    FONGHER, C
    SABADIN, L
    FRATTON, MG
    VALERIO, A
    TIENGO, A
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 262 (04): : E455 - E463
  • [5] Splanchnic versus whole-body production of alpha-ketoisocaproate from leucine in the fed state
    Biolo, G
    Tessari, P
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (02): : 164 - 167
  • [6] Branched-chain amino acids: Enzyme and substrate regulation
    Brosnan, JT
    Brosnan, ME
    [J]. JOURNAL OF NUTRITION, 2006, 136 (01) : 207S - 211S
  • [7] POSSIBLE REGULATOR OF PROTEIN TURNOVER IN MUSCLE
    BUSE, MG
    REID, SS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (05) : 1250 - 1261
  • [8] DIRECT DETERMINATION OF LEUCINE METABOLISM AND PROTEIN BREAKDOWN IN HUMANS USING L-[1-C-13, N-15]-LEUCINE AND THE FOREARM MODEL
    CHENG, KN
    DWORZAK, F
    FORD, GC
    RENNIE, MJ
    HALLIDAY, D
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1985, 15 (06) : 349 - 354
  • [9] Cohen PP, 1941, J BIOL CHEM, V140, P711
  • [10] FRICK GP, 1988, J BIOL CHEM, V263, P3245